EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

A dose escalation safety study of intravenous tissue plasminogen activator in patients treated from 90 to 180 minutes from onset of acute ischemic stroke



A dose escalation safety study of intravenous tissue plasminogen activator in patients treated from 90 to 180 minutes from onset of acute ischemic stroke



Annals of Neurology 28(2): 225




(PDF emailed within 1 workday: $29.90)

Accession: 029645121

Download citation: RISBibTeXText



Related references

Intra-arterial thrombolysis after full-dose intravenous recombinant tissue plasminogen activator for patients older than 80 years with acute ischemic stroke: what is the safety limit?. Neurology India 58(3): 487-487, 2010

Effectiveness and safety of a single intravenous bolus injection of tissue-type plasminogen activator in acute myocardial infarction. Bolus Dose-Escalation Study of Tissue-Type Plasminogen Activator (BEST) Investigators. American Journal of Cardiology 69(17): 1393-1398, 1992

Safety of full-dose intravenous recombinant tissue plasminogen activator followed by multimodal endovascular therapy for acute ischemic stroke. Journal of Neurointerventional Surgery 5(4): 298-301, 2014

Endovascular thrombectomy for acute ischemic stroke in failed intravenous tissue plasminogen activator versus non-intravenous tissue plasminogen activator patients: revascularization and outcomes stratified by the site of arterial occlusions. Stroke 41(6): 1185-1192, 2010

Intravenous recombinant tissue plasminogen activator for acute ischemic stroke: a feasibility and safety study. International Journal of General Medicine 9(): 361-367, 2016

Low-dose versus standard-dose tissue plasminogen activator for intravenous thrombolysis in Asian acute ischemic stroke patients. Stroke 41(8): E545-6; Author Reply E547-8, 2010

Efficacy and safety of a modified intravenous recombinant tissue plasminogen activator regimen in Chinese patients with acute ischemic stroke. Journal of Stroke and Cerebrovascular Diseases 22(5): 690-693, 2014

Safety and Effectiveness of Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator in 80 Years and Older Acute Ischemic Stroke Patients. Cell Biochemistry and Biophysics 72(3): 883-888, 2016

Risk score for intracranial hemorrhage in patients with acute ischemic stroke treated with intravenous tissue-type plasminogen activator. Stroke 43(9): 2293-2299, 2012

Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator. JAMA 307(24): 2600-2608, 2012

Risk of pneumonia associated with zero-degree head positioning in acute ischemic stroke patients treated with intravenous tissue plasminogen activator. Brain and Behavior 6(2): E00425-E00425, 2016

Risks and Benefits Associated With Prestroke Antiplatelet Therapy Among Patients With Acute Ischemic Stroke Treated With Intravenous Tissue Plasminogen Activator. JAMA Neurology 73(1): 50-59, 2016

Drill down analysis of door-to-needle time of acute ischemic stroke patients treated with intravenous tissue plasminogen activator. American Journal of Emergency Medicine 32(11): 1330-1333, 2015

Safety and effectiveness of intravenous thrombolysis with recombinant tissue plasminogen activator in eighty years and older acute ischemic stroke patients. European Review for Medical and Pharmacological Sciences 19(10): 1852-1858, 2016

Symptomatic intracerebral hemorrhage among eligible warfarin-treated patients receiving intravenous tissue plasminogen activator for acute ischemic stroke. Archives of Neurology 67(5): 559-563, 2010